ArticleAmerican journal of translational research2020
A seven immune-related lncRNA signature predicts the survival of patients with colon adenocarcinoma.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Downregulated LINC02381 Predicts Tumor Progression and Correlates with Poor Survival in Gastric Cancer.International journal of general medicine · 2026Article
- Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications.Non-coding RNA research · 2024Review
- Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment.Journal of orthopaedic surgery and research · 2023Article
- Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.Journal of cancer research and clinical oncology · 2023Article
- Construction of a new immune-related lncRNA model and prediction of treatment and survival prognosis of human colon cancer.World journal of surgical oncology · 2022Article
- A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer.Journal of oncology · 2022Article
- A Prognostic Model of Bladder Cancer Based on Metabolism-Related Long Non-Coding RNAs.Frontiers in oncology · 2022Article
- Ferroptosis-Related Long Noncoding RNAs as Prognostic Marker for Colon Adenocarcinoma.Applied bionics and biomechanics · 2022Article
- Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.Frontiers in genetics · 2022Article
- Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer.Frontiers in oncology · 2022Article
- Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition.Journal of translational medicine · 2021Article
- Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model.Frontiers in genetics · 2021Article
- A Novel Signature Constructed by Immune-Related LncRNA Predicts the Immune Landscape of Colorectal Cancer.Frontiers in genetics · 2021Article
- Genome Instability and Long Noncoding RNA Reveal Biomarkers for Immunotherapy and Prognosis and Novel Competing Endogenous RNA Mechanism in Colon Adenocarcinoma.Frontiers in cell and developmental biology · 2021Article
- Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer.Frontiers in genetics · 2021Article
- Using Immune-Related Long Non-coding Ribonucleic Acids to Develop a Novel Prognosis Signature and Predict the Immune Landscape of Colon Cancer.Frontiers in cell and developmental biology · 2021Article
- Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore immune-related lncRNAs for predicting the overall survival of patients with colon adenocarcinoma. RNA-sequencing data were downloaded from the TCGA data portal. The immune-related lncRNAs with differential expression were identified with Cox and LASSO regression analysis. With the stepwise regression analysis, a seven lncRNA signature was established for calculating the Risk Score with following formula: Risk Score = [Expression level of AC027307.2 * (0.156)] + [Expression level of AC074117.1 * (0.294)] + [Expression level of AC103702.2 * (-0.025)] + [Expression level of CYTOR * (0.205)] + [Expression level of LINC02381 * (0.251)] + [Expression level of MIR200CHG * (0.052)] + [Expression level of SNHG16 * (-0.101)]. The Risk Score was validated with survival analysis, achieving moderate area under the curve (AUC) of receiver operating characteristic (ROC) curve over 0.7. GSEA and immune-cell abundance analysis further supported the involved lncRNAs were immune-relevant. Finally, the prognosis prediction efficacy was verified with clinical samples with an AUC of 0.674 in ROC curve. Both the Risk Score and involved immune-related lncRNAs presented promising clinical significance.
Indexed as
Identifiers
33312351PMC7724340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.